Videos

Elinzanetant, a non-hormonal drug, shows promising results in reducing hot flashes and night sweats, offering a new option for women seeking effective and safe treatment for vasomotor symptoms.

Matthew Nudy, MD, discusses his team's findings on hormone therapy and cardiovascular effects at the 2024 Annual Meeting of the Menopause Society.

Learn how self-advocacy, preparation, and collaboration with doctors can help women gain control over their health and live more fully, free from stigma and shame.

Discover how deepening understanding and providing vetted resources can empower women to reclaim their wellness and navigate the powerful impacts of menopause with confidence.

Fezolinetant offers women a groundbreaking, non-hormonal solution to manage menopause symptoms like hot flashes and sleep disturbances, supported by large clinical trials.

Research reveals that environmental exposures and PTSD from Gulf War service significantly increase the likelihood of early menopause, highlighting the need for targeted reproductive health care for women veterans.

Vanessa Muñiz presents research comparing clinical hypnosis and cognitive behavioral therapy for treating hot flashes, revealing that hypnosis significantly reduces frequency and improves quality of life.

Stephanie Faubion, MD, MBA, medical director of the Menopause Society, shares details from her presentation on hormone therapy at the 2024 Annual Meeting of The Menopause Society.

Lauren Streicher, MD, advocates for practical, individualized solutions for postmenopausal sexual dysfunction, emphasizing increased vascularization, stimulation, and addressing related symptoms.

The phase 3 OASIS trial presented at the 2024 Annual Meeting of The Menopause Society displayed significant improvements in the frequency of moderate-to-severe vasomotor symptoms among patients receiving elinzanetant.

In this video from The Menopause Society Annual Meeting, Lauren Streicher, MD, talks about what to ask your patients about sexual function.

At the 2024 Menopause Society meeting, JoAnn Pinkerton, MD, highlighted phase 3 long-term safety data of elinzanetant from the OASIS 3 trial.

A discussion of vasomotor symptoms and the potential benefits of elinzanetant with Nanette Santoro, MD, from The Menopause Society annual meeting in Chicago, Illinois.

Nanette Santoro, MD, and Lauren Streicher, MD, MSCP, briefly highlight why they feel the annual Menopause Society is a great place for learning and collaboration.

Amanda Williams, MD, MPH, FACOG, Interim Chief Medical Officer at March of Dimes, discusses the reported increase in the number of US counties with no obstetric care providers.

In this episode, clinicians discuss challenges associated with these topics and offer some insights on them.

A study discussed by Tabby Khan, MD. MPH, reveals low rates of low-dose aspirin use among high-risk preeclampsia patients, highlighting the need for increased clinician awareness and better insurance coverage to improve maternal and infant health outcomes.

Kristyn Brandi, MD, MPH, FACOG, discusses the Supreme Court's decision to maintain mifepristone availability and its potential impact on future women's health cases.

In an interview with Contemporary OB/GYN, Bianca Hall, DO, MSCR, discusses the Supreme Court’s decision affirming mifepristone's safety and accessibility, emphasizing its role in providing comprehensive abortion care.

Risa Kagan, MD, discusses the efficacy of fezolinetant in reducing the frequency and severity of vasomotor symptoms in menopausal women, offering an alternative to traditional hormonal therapies.

Wanda Barfield, MD, MPH, highlights significant racial disparities in maternal mortality and emphasizes the importance of collaborative efforts and data-driven approaches to improve maternal health outcomes in the United States.

Mary Claire B. Manske, MD, discusses her findings on the unexplained increased risk of brachial plexus birth injury among Black and Hispanic infants, highlighting the need for improved prenatal care and further research.

A symposium at ACOG 2024 focused on how to boost clinician confidence when it comes to contraception education for this patient population.

Experts discuss the necessity of evolving prenatal care through innovative models to better meet patient needs and incorporate advances such as telemedicine.

Dive into the research presented by Rhonda R. Voskuhl at ACOG 2024, shedding light on the potential of estrogen receptor beta as a target to mitigate cognitive decline in postmenopausal women.

At ACOG 2024, Monica M. Christmas, MD, FACOG, and Stephanie Faubion, MD, emphasize the importance of combating disinformation in menopause care and provide clinicians with evidence-based strategies to manage symptoms effectively.

Raanan Meyer, MD, shares the results and takeaways from his ACOG 2024 study on a 24-hour compared with 12-hour mifepristone-misoprostol regimen for second-trimester abortion, including the impact on patient satisfaction.

At the 2024 ACOG Annual Clinical & Scientific Meeting, experts emphasized the importance of equipping ob-gyns with the knowledge and tools to address sexual health issues, including hyperactive sexual desire disorder, anorgasmia, and pelvic pain.

Phase 3 data presented by JoAnn Pinkerton, MD, reveals that elinzanetant significantly improves hot flash frequency, sleep, and overall menopause quality of life, offering a promising alternative to estrogen therapy.

Alison Edelman, MD, MPH, dives into her research presented at the 2024 ACOG Annual Clinical and Scientific Meeting on COVID-19 vaccination and it's impact on the menstrual cycle.